Clinical Trial Update: Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating tolvaptan in children and adolescents with autosomal dominant polycystic kidney disease has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 3 | Status: COMPLETED | Results posted: 2023-01-03